ForlenzaGP, LiZ, BuckinghamBA, et al.Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG Trial. Diabetes Care, 2018; 41: 2155–2161.
2.
BuckinghamBA, ForlenzaGP, PinskerJE, et al.Safety and feasibility of the OmniPod hybrid closed-loop system in adult, adolescent, and pediatric patients with type 1 diabetes using a personalized model predictive control algorithm. Diabetes Technol Ther, 2018; 20: 257–262.
3.
BuckinghamBA, ChristiansenMP, ForlenzaGP, et al.Performance of the Omnipod personalized model predictive control algorithm with meal bolus challenges in adults with type 1 diabetes. Diabetes Technol Ther, 2018; 20: 585–595.
4.
DadlaniV, PinskerJE, DassauE, KudvaYC. Advances in closed-loop insulin delivery systems in patients with type 1 diabetes. Curr Diab Rep, 2018; 18: 88.
5.
BallyL, ThabitH, HartnellS, et al.Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med, 2018; 379: 547–556.
6.
StewartZA, WilinskaME, HartnellS, et al.Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: a randomized controlled crossover trial. Diabetes Care, 2018; 41: 1391–1399.
7.
DreaMed Diabetes. DreaMed Diabetes granted FDA authorization to market Advisor Pro, offering personalized optimization of insulin pump therapy. https://dreamed-diabetes.com/dreamed-diabetes-granted-fda-authorization-to-market-advisor-pro-offering-personalized-optimization-of-insulin-pump-therapy (Accessed 8/5/2018).
8.
JacobsPG, El YoussefJ, ReddyR, et al.Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. Diabetes Obes Metab, 2016; 18: 1110–1119.
9.
ThabitH, HartnellS, AllenJM, et al.Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes Endocrinol, 2017; 5: 117–124.
10.
CastleJR, El YoussefJ, WilsonLM, et al.Randomized outpatient trial of single- and dual-hormone closed-loop systems that adapt to exercise using wearable sensors. Diabetes Care, 2018; 41: 1471–1477.
11.
HaidarA, LegaultL, Matteau-PelletierL, et al.Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol, 2015; 3: 595–604.
12.
PinskerJE, KrausA, GianferanteD, et al.Techniques for exercise preparation and management in adults with type 1 diabetes. Can J Diabetes, 2016; 40: 503–508.
13.
ZisserH, RenardE, KovatchevB, et al.Multicenter closed-loop insulin delivery study points to challenges for keeping blood glucose in a safe range by a control algorithm in adults and adolescents with type 1 diabetes from various sites. Diabetes Technol Ther, 2014; 16: 613–622.
14.
Del FaveroS, PlaceJ, KropffJ, et al.Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes. Diabetes Obes Metab, 2015; 17: 468–476.
15.
ThabitH, ElleriD, LeelarathnaL, et al.Unsupervised overnight closed loop insulin delivery during free living: analysis of randomised cross-over home studies in adults and adolescents with type 1 diabetes. Lancet, 2015; 385: S96.
16.
KropffJ, Del FaveroS, PlaceJ, et al.2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol, 2015; 3: 939–947.
17.
NimriR, MullerI, AtlasE, et al.MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care, 2014; 37: 3025–3032.
18.
HarveyRA, DassauE, BevierWC, et al.Clinical evaluation of an automated artificial pancreas using zone-model predictive control and health monitoring system. Diabetes Technol Ther, 2014; 16: 348–357.
19.
BuckinghamBA, RaghinaruD, CameronF, et al.Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis. Diabetes Care, 2015; 38: 1197–1204.
20.
MaahsDM, CalhounP, BuckinghamBA, et al.A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care, 2014; 37: 1885–1891.
21.
SpaicT, DriscollM, RaghinaruD, et al.Predictive hyperglycemia and hypoglycemia minimization: in-home evaluation of safety, feasibility, and efficacy in overnight glucose control in type 1 diabetes. Diabetes Care, 2017; 40: 359–366.
22.
WeismanA, BaiJW, CardinezM, KramerCK, PerkinsBA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol, 2017; 5: 501–512.
